ተጨማሪ መረጃ ― አማርኛ

Acanthosis nigricans የቆዳ በሽታ መገለጫ ነው። ብዙውን ጊዜ እንደ ኋላና ጎን ጭብጥ የቆዳ ሽታዎች ላይ ይታያል፣ ይህም ግልጽ ባልሆኑ ጠርዞች እንደ ቬልቬቲ (velvety) ጥቁር ፕላክ (plaque) ይመስላል። ይህ ሁኔታ ብዙውን ጊዜ ከዲያቤቲስ ሜለትስ (diabetes mellitus) እና ከኢንሱሊን ተቃውሞ (insulin resistance) ጋር የተያያዘ ነው, ነገር ግን አልፎ አልፎ, በሰውነት ውስጥ ካንሰርን ሊያመለክት ይችላል። በተጨማሪም በሆርሞን ጉዳዮች ወይም እንደ ስተሮይድ (steroid) እና የወሊድ መከላከያ ክኒኖች (oral contraceptives) ያሉ ልዩ መድሃኒቶችን በመውሰድ ሊታይ ይችላል።
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.

Acanthosis nigricans (AN) እንደ ኢንሱሊን ተቃውሞ (insulin resistance), የስኳር በሽታ (diabetes mellitus), ተጨማሪ ውፍረት (obesity), የተወሰኑ ካንሰሮች (cancers), ሆርሞን ችግሮች (hormonal disorders) እና የመድሃኒት ምላሽ (drug reactions) ጋር የተገናኘ የተለመደ የቆዳ በሽታ ነው። ኤኤንን ማከም በመሰረታዊ የጤና ችግሮችን በመፍታት ላይ ያተኩራል። መጀመሪያ ላይ ዶክተሮች የኢንሱሊን ተቃውሞ (insulin resistance) ሲንድሮም ምልክቶችን ይመርምራሉ, ይህም ተጨማሪ ውፍረት (obesity), ከፍተኛ ኮሌስትሮል (hypercholesterolemia), የደም ግፊት (hypertension) እና ዓይነት 2 የስኳር በሽታ (type 2 diabetes mellitus) ያጠቃልላል። ዶክተሮች ብዙውን ጊዜ topical retinoids እንደ መጀመሪያው የሕክምና ምርጫ ያዝዛሉ, ይህም ለቆዳ ውፍረት ይረዳል። ነገር ግን፣ የቆዳ መጨለምን ሙሉ በሙሉ ላያስተናግዱ ይችላሉ። ሌሎች የሕክምና አማራጮች (salicylic acid, podophyllin, urea, calcipotriol) እንዲሁ ተደጋጋሚ ማመልከቻ ያስፈልጋቸዋል።
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.